The Natural Killer (NK) Cell Therapeutics market is experiencing significant growth, driven by increasing research into immunotherapy, rising cancer prevalence, and advancements in cell-based treatments. NK cell therapies offer promising alternatives for cancer and infectious disease treatments due to their ability to target abnormal cells with high precision. The market is fueled by growing investments in biotechnology, strategic collaborations between pharmaceutical companies, and supportive regulatory frameworks for cell-based therapies. Despite this, the increasing adoption of NK cell therapies in oncology and the ongoing clinical trials suggest a strong potential for future growth.
Global Natural Killer (NK) Cell Therapeutics Market is growing with CAGR of 43.1% during the forecast period 2023 to 2030.
To know more, visit https://www.databridgemarketresearch.com/reports/global-natural-killer-nk-cell-therapeutics-market
Below are the Top Natural Killer (NK) Cell Therapeutics Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
Merck KGaA
|
Merck KGaA is actively engaged in the development of immuno-oncology therapies, including those targeting Natural Killer (NK) cells. The company is exploring innovative approaches to harness the innate immune system's potential to recognize and eliminate cancer cells. Specific NK cell-based therapies from Merck KGaA are part of their broader oncology pipeline aimed at providing novel treatment options for various malignancies.
|
|
Africa, Asia, Europe, Latin America, North America, Oceania
|
In June 2020, Merck KGaA received approval for BAVENCIO, a PD-L1 targeted NK –cell therapy for treatment of locally advanced or metastatic urothelial carcinoma. This approval has helped the company to enhance its product portfolio for cancer treatment.
|
|
2.
|
Bristol-Myers Squibb Company
|
BMS has demonstrated a strong commitment to advancing NK cell therapeutics through strategic collaborations and acquisitions. In March 2025, BMS announced the acquisition of 2seventy bio, a company specializing in cancer cell therapies, for approximately $286 million. This acquisition is expected to enhance BMS's cell therapy portfolio, particularly in the development of treatments like Abecma, a CAR T-cell therapy for multiple myeloma.
|
Bempegaldesleukin
|
North America, Asia-Pacific, and Europe
|
In August 2020, Bristol-Myers Squibb Company received positive result from phase 3 clinical trial result of Opdivo (nivolumab) for treatment of disease arising after the resection of oesophageal or gastroesophageal junction cancer. This product is NK cell based therapy and hence this result paved the way for the company to get product approval.
|
|
3.
|
Glycostem
|
Glycostem Therapeutics is a biotechnology company focused on the development of allogeneic NK cell therapies for cancer treatment. Their lead product, oNKord, is an off-the-shelf NK cell therapy derived from umbilical cord blood. oNKord is designed to target and eliminate cancer cells in patients with hematological malignancies and solid tumors.
|
|
Europe
|
In July 2020, Glycostem collaborated with the LUMICKS in order to enhance the NK- cell mediated immunotherapy. This collaboration allowed the company to add z-Movi to its product development procedure which improved the development of NK- cell based therapy.
|
|
4.
|
Regeneron Pharmaceuticals Inc.
|
Regeneron Pharmaceuticals is actively involved in the development of immunotherapies, including those targeting NK cells. The company focuses on leveraging its proprietary technologies to discover and develop novel therapeutics that enhance the body's immune response against cancer.
|
REGN1979
|
North America, Europe
|
In April 2020, Regeneron Pharmaceuticals Inc. went under the collaboration with Zai Lab Limited for development and commercialization of REGN1979 (CD20xCD3 bispecific antibody) which is designed to trigger tumor killing by activating NK cells bind to CD 20. This collaboration has allowed the company to accelerate the development of REGN1979.
|
|
5.
|
Takeda Pharmaceutical Company Limited
|
Takeda Pharmaceutical Company is engaged in the research and development of NK cell-based therapies as part of its broader oncology portfolio. The company is exploring innovative approaches to harness NK cells' natural cytotoxic abilities to target and destroy cancer cells.
|
TAK- 007
|
Middle East and Africa, Asia, Europe, Americas
|
In November 2019, Takeda Pharmaceutical Company Limited went under the collaboration with MD Anderson in order to accelerate the development of off- the shelf CAR- NK cell therapy platform. This collaboration allowed the company to accelerate the development of NK cell therapy for treatment of malignancies.
|
Conclusion
The NK Cell Therapeutics market is set for robust expansion as the demand for innovative immunotherapies rises. Continued advancements in biotechnology, along with supportive government policies and private investments, will likely accelerate the commercialization of NK cell therapies. While regulatory and manufacturing challenges remain, the increasing pipeline of clinical trials and breakthrough approvals indicate a promising future. Key industry players are expected to drive market growth through strategic collaborations, acquisitions, and technological innovations, ensuring a competitive and dynamic market landscape.
